Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | PRESIDENT AND COO | May 13, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $217.50 · Expires 2033-03-15 | Direct | 0 |
Reported balance
After 2026-05-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-13 · Gift · Disposed 11,728 · Balance 0 F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $217.50 · Expires 2033-03-15 | Indirectby Trust | 99,720 |
Reported balance
After 2026-05-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-13 · Gift · Acquired 11,728 · Balance 99,720 F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. F2: Held in trusts beneficially owned by the Reporting Person, of which the Reporting Person or his family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 13, 2026, the Reporting Person transferred stock options to a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
F2: Held in trusts beneficially owned by the Reporting Person, of which the Reporting Person or his family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 377 | $458.74 | $172,943.55 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,063 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $458.38 to $459.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 372 | $457.92 | $170,345.50 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,440 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $457.36 to $458.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 63 | $456.87 | $28,782.51 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,812 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $456.34 to $457.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,875 | $146.03 | $1,149,986.25 |
DisclosureSEC source: 0001673232-26-000007 · primarydocument.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock · Derivative | 14,625 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · derivative · entry 17 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 67,875 Underlying: Common Stock · 14,625 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 26 | $470.76 | $12,239.63 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 15 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 156 | $470.37 | $73,377.72 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 14 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 26 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F15 · price: This transaction was executed in multiple trades at prices ranging from $469.73 to $470.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 837 | $469.18 | $392,704.08 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 13 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 182 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F14 · price: This transaction was executed in multiple trades at prices ranging from $468.73 to $469.65. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,922 | $468.12 | $1,367,836.41 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 12 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 1,019 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F13 · price: This transaction was executed in multiple trades at prices ranging from $467.73 to $468.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 596 | $467.09 | $278,386.30 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 11 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 3,941 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F12 · price: This transaction was executed in multiple trades at prices ranging from $466.73 to $467.70. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,055 | $466.06 | $491,697.20 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 10 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 4,537 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $465.62 to $466.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,794 | $465.11 | $834,406.62 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 9 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 5,592 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $464.62 to $465.615. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,274 | $464.06 | $1,055,263.80 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 8 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,386 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $463.61 to $464.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,456 | $463.26 | $1,137,768.03 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 9,660 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $462.61 to $463.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 503 | $461.12 | $231,942.76 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 12,116 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $460.56 to $461.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 498 | $459.87 | $229,012.82 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 5 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 12,619 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $459.55 to $460.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 700 | $458.74 | $321,115.76 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 13,117 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $458.38 to $459.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 692 | $457.92 | $316,879.12 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 13,817 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $457.36 to $458.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 116 | $456.87 | $52,996.49 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14,509 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $456.34 to $457.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 20, 2026 Filed Jan 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 14,625 | $117.76 | $1,722,240.00 |
DisclosureSEC source: 0001673232-26-000006 · primarydocument.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,875 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-26-000005 · primarydocument.xml · derivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 44,440 Underlying: Common Stock · 7,875 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 14,625 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001673232-26-000005 · primarydocument.xml · derivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 82,500 Underlying: Common Stock · 14,625 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 7,875 | $479.51 | $3,776,106.60 |
DisclosureSEC source: 0001673232-26-000005 · primarydocument.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 7,875 | $146.03 | $1,149,986.25 |
DisclosureSEC source: 0001673232-26-000005 · primarydocument.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 14,625 | $479.51 | $7,012,769.40 |
DisclosureSEC source: 0001673232-26-000005 · primarydocument.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 22:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 14,625 | $117.76 | $1,722,240.00 |
DisclosureSEC source: 0001673232-26-000005 · primarydocument.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 14,625 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · derivative · entry 17 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 97,125 Underlying: Common Stock · 14,625 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 797 | $494.27 | $393,935.02 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 15 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F16 · price: This transaction was executed in multiple trades at prices ranging from $493.99 to $494.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 374 | $493.47 | $184,559.24 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 14 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 797 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F15 · price: This transaction was executed in multiple trades at prices ranging from $492.96 to $493.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,110 | $492.44 | $546,613.28 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 13 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 1,171 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F14 · price: This transaction was executed in multiple trades at prices ranging from $491.91 to $492.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,201 | $491.35 | $590,110.75 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 12 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 2,281 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F13 · price: This transaction was executed in multiple trades at prices ranging from $490.90 to $491.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,659 | $490.11 | $813,093.65 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 11 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 3,482 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F12 · price: This transaction was executed in multiple trades at prices ranging from $489.90 to $490.885. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 677 | $489.49 | $331,384.53 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 10 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 5,141 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $488.90 to $489.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,189 | $488.38 | $580,679.42 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 9 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 5,818 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $487.90 to $488.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 856 | $487.40 | $417,217.57 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 8 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,007 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $486.79 to $487.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,669 | $486.05 | $811,217.45 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 7 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 7,863 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $485.58 to $486.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,169 | $485.00 | $566,959.16 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 6 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 9,532 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $484.54 to $485.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 697 | $483.80 | $337,211.67 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 5 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 10,701 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $483.47 to $484.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 873 | $482.72 | $421,413.51 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 4 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 11,398 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $482.34 to $483.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,657 | $481.86 | $798,446.49 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 3 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 12,271 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $481.32 to $482.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 697 | $480.68 | $335,035.42 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 2 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 13,928 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $480.32 to $481.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 14,625 | $117.76 | $1,722,240.00 |
DisclosureSEC source: 0001673232-26-000004 · primarydocument.xml · nonDerivative · entry 1 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 14,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F2 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person is a beneficiary, and as to which the Reporting Person and his spouse are co-trustees and have shared investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 7,875 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001673232-26-000003 · primarydocument.xml · derivative · entry 17 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 52,315 Underlying: Common Stock · 7,875 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F16 · ownership.nature: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 429 | $494.27 | $212,042.86 |
DisclosureSEC source: 0001673232-26-000003 · primarydocument.xml · nonDerivative · entry 15 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 0 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F16 · price: Reflects the exercise of options, and sale of the resulting shares of common stock, held in a trust beneficially owned by the Reporting Person, of which the Reporting Person's family members are beneficiaries, and as to which the Reporting Person has sole investment and voting power. F2 · ownership.nature: This transaction was executed in multiple trades at prices ranging from $480.32 to $481.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 201 | $493.47 | $99,188.11 |
DisclosureSEC source: 0001673232-26-000003 · primarydocument.xml · nonDerivative · entry 14 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 429 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F15 · price: This transaction was executed in multiple trades at prices ranging from $493.99 to $494.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: This transaction was executed in multiple trades at prices ranging from $480.32 to $481.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 598 | $492.44 | $294,481.81 |
DisclosureSEC source: 0001673232-26-000003 · primarydocument.xml · nonDerivative · entry 13 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 630 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F14 · price: This transaction was executed in multiple trades at prices ranging from $492.96 to $493.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: This transaction was executed in multiple trades at prices ranging from $480.32 to $481.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 647 | $491.35 | $317,903.19 |
DisclosureSEC source: 0001673232-26-000003 · primarydocument.xml · nonDerivative · entry 12 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 1,228 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F13 · price: This transaction was executed in multiple trades at prices ranging from $491.91 to $492.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: This transaction was executed in multiple trades at prices ranging from $480.32 to $481.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 893 | $490.11 | $437,668.68 |
DisclosureSEC source: 0001673232-26-000003 · primarydocument.xml · nonDerivative · entry 11 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 1,875 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F12 · price: This transaction was executed in multiple trades at prices ranging from $490.90 to $491.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: This transaction was executed in multiple trades at prices ranging from $480.32 to $481.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 364 | $489.49 | $178,174.43 |
DisclosureSEC source: 0001673232-26-000003 · primarydocument.xml · nonDerivative · entry 10 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 2,768 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $489.90 to $490.885. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: This transaction was executed in multiple trades at prices ranging from $480.32 to $481.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 641 | $488.38 | $313,049.40 |
DisclosureSEC source: 0001673232-26-000003 · primarydocument.xml · nonDerivative · entry 9 BENKOWITZ MICHAEL · CIK 0001673232 · PRESIDENT AND COO 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 3,132 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $488.90 to $489.89. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: This transaction was executed in multiple trades at prices ranging from $480.32 to $481.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.